FDA approved Cyramza (ramucirumab), sponsored by Eli Lilly, as a single agent for hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥ 400 ng/mL and have been previously treated with sorafenib.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
